Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Protein Linked To Change In Tissue That Surround And Support Breast Tumors
A protein known to be overly active in breast cancer can exist in a form that seems to change the structural composition of mammary tissue, potentially making it more conducive to tumor progression, say researchers from the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC).
generic viagra online
Roche Launches New PCR Assay For Tuberculosis Testing In South Africa
Roche Diagnostics announced the launch of a new tuberculosis test for South Africa. Worldwide, South Africa is one of the countries with the highest prevalence of tuberculosis. The new kit detects different species of Mycobacterium from human sputum samples using the LightCycler® 2.0 Instrument.
News of the day
MADIT-CRT Trial Meets Primary Endpoint
Boston Scientific Corporation (NYSE: BSX) and the University of Rochester Medical Center announced that the landmark MADIT-CRT trial has met its primary endpoint. Preliminary results show Boston Scientific cardiac resynchronization therapy defibrillators (CRT-Ds) to be associated with a significant 29 percent reduction (p=0.003) in death or heart failure interventions when compared to traditional implantable cardioverter defibrillators (ICDs). High risk(1), asymptomatic or mildly symptomatic, New York Heart Association (NYHA) Class I and II(2) patients were enrolled in MADIT-CRT. The MADIT-CRT Executive Committee expects to present and publish the trial"s full results later this year.
Mental Health

Amarillo Biosciences Announces Completion Of Screening Process For Influenza Study In Australia

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) announced that the screening of volunteers for inclusion in a Phase 2 clinical study of the company"s oral interferon product at the University of Western Australia is now complete. The investigators met their target of screening at least 200 healthy adults for participation in the trial. A total of 215 volunteers were evaluated and 134 of them have been enrolled into the study to date. About 90% of the screened subjects have been found to qualify for the study, so additional enrollments are expected over the next 2 weeks to bring the total number of study participants up to or above the targeted 160 subjects. The double-blind, placebo-controlled Phase 2 clinical trial is being conducted by Dr. Manfred Beilharz and colleagues. The study is expected to show that lozenges containing a low dose of interferon-alpha can prevent infection or reduce the severity of infection with influenza and other common respiratory viruses when taken once a day during a typical winter cold/flu season. Dr. Joseph Cummins, President and CEO of ABI, said, "We are pleased that Dr. Beilharz and his study team were able to achieve their goal of screening over 200 volunteers because this study is an important step in proving that our low-dose interferon lozenges can be a safe and effective alternative to antiviral drugs for influenza. New therapies like oral interferon are needed in the face of the ongoing swine flu pandemic, especially since the influenza virus has developed resistance in the past to currently marketed antiviral drugs." Dr. Manfred Beilharz said, "The community spread of swine flu in Perth has gone from 0 to 80+ in 14 days, and that is only the confirmed cases. Over the next 3 months we here in Perth, Western Australia may well experience a reproduction of the community spread that is occurring in Melbourne, Victoria. If our lozenges work as well as we anticipate against swine flu, we will make a tremendous contribution to economical public health procedures." Amarillo Biosciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009